Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
Celldex Therapeutics, Inc. (CLDX) had Return on Equity of -10.29% for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
$0.02M |
|
$-73.50M |
|
-- |
|
$0.02M |
|
$80.64M |
|
$-80.62M |
|
$7.12M |
|
$-73.50M |
|
$-73.50M |
|
$-73.50M |
|
$-73.50M |
|
$-73.50M |
|
$-73.50M |
|
$-80.62M |
|
$-81.42M |
|
77.84M |
|
77.84M |
|
$-0.94 |
|
$-0.94 |
|
| Balance Sheet Financials | |
$724.93M |
|
$9.76M |
|
$57.42M |
|
$782.35M |
|
$61.33M |
|
-- |
|
$6.46M |
|
$67.78M |
|
$714.56M |
|
$687.37M |
|
$714.56M |
|
78.50M |
|
| Cash Flow Statement Financials | |
$-123.00M |
|
$-183.40M |
|
$324.98M |
|
$28.87M |
|
$47.45M |
|
$18.58M |
|
$16.93M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
11.82 |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
100.00% |
|
-366468.20% |
|
-366468.20% |
|
-- |
|
-334104.50% |
|
-334104.50% |
|
$-127.82M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
0.10 |
|
940.91 |
|
|
Return on Equity |
-10.29% |
-10.69% |
|
-9.40% |
|
-10.29% |
|
$9.10 |
|
$-1.64 |
|
$-1.58 |
|